ODN/Pam2 Drug Asset Due Diligence Report 2026

This ODN/Pam2 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether ODN/Pam2 can convert its CpG ODN profile and TLR2 x TLR6 x TLR9 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	ODN/Pam2 (query alias: ODN/Pam2)
Modality / target	CpG ODN; TLR2 x TLR6 x TLR9; TLR2 agonists, TLR6 agonists, TLR9 agonists
Highest global status	Phase 2
Originator	Pulmotect, Inc.
Active developers	Pulmotect, Inc., UT MD Anderson Cancer Center

The MCP disease footprint includes Hematopoietic stem cell transplantation, Leukemia, Lower Respiratory Tract Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06665100	Phase 2	Recruiting	100	Primary endpoint not disclosed in English source
NCT04312997	Phase 2	Completed	101	Primary endpoint not disclosed in English source
NCT04313023	Phase 2	Completed	217	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

Phase 2; n=217; evaluation: Not stated in English source. Reported fields: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of Experimental Therapy.(LS Mean) = 0.028 Point (90%CI, -0.004 to 0.060); Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of Experimental Therapy.(LS Mean) = 0.048 Point (90%CI, 0.017 - 0.079)

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Phase 2; n=101; evaluation: Not stated in English source. Reported fields: Number of Participants With Worsening of COVID-19 Within 28 Days = 1 Pts ; Number of Participants With Worsening of COVID-19 Within 28 Days = 1 Pts

Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19

Phase 2; n=217; evaluation: Negative. Reported fields: OSCI = no statistically significant difference ; OSCI = no statistically significant difference

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

ODN/Pam2 addresses Hematopoietic stem cell transplantation, Leukemia, Lower Respiratory Tract Infections. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—CpG ODN—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 8 matched transaction record(s) under the scope “target-level comparable: TLR2 x TLR6 x TLR9.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TLR2 x TLR6 x TLR9 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
Not disclosed	Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment	Preclinical	Financial terms not disclosed
2022-08-22	CHA University Bundang Medical Center collaborates on research for CHA Vaccine Institute's L-pampo in cancer treatment.	Preclinical	Financial terms not disclosed
2022-05-10	Bioasis and Neuramedy Enter into Research Collaboration and License Agreement	Preclinical	US$72.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Prolyl hydroxylase domain-containing protein (PHD) inhibitors, combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ARDS) in coronavirus disease (covid-19)”. The milestone feed surfaced a patent-application signal described as “Oral delivery of oligonucleotides”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO